ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. increased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 241.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,626 shares of the biotechnology company’s stock after acquiring an additional 76,121 shares during the period. Roman Butler Fullerton & Co.’s holdings in ADMA Biologics were worth $2,151,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ADMA. BNP Paribas Financial Markets boosted its stake in ADMA Biologics by 152.2% during the first quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock valued at $4,837,000 after buying an additional 442,315 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of ADMA Biologics by 707.3% during the 1st quarter. GSA Capital Partners LLP now owns 134,929 shares of the biotechnology company’s stock valued at $891,000 after purchasing an additional 118,215 shares in the last quarter. LSV Asset Management acquired a new position in shares of ADMA Biologics in the 1st quarter worth approximately $1,028,000. Mesirow Institutional Investment Management Inc. bought a new stake in shares of ADMA Biologics in the 1st quarter worth approximately $17,221,000. Finally, ClariVest Asset Management LLC lifted its stake in ADMA Biologics by 186.2% during the first quarter. ClariVest Asset Management LLC now owns 569,225 shares of the biotechnology company’s stock valued at $3,757,000 after purchasing an additional 370,319 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ADMA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of ADMA Biologics in a research report on Monday, October 14th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $15.50.

ADMA Biologics Stock Up 18.8 %

Shares of NASDAQ:ADMA opened at $19.37 on Monday. The firm has a 50 day simple moving average of $17.85 and a 200 day simple moving average of $13.46. ADMA Biologics, Inc. has a 52 week low of $3.40 and a 52 week high of $21.13. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The company has a market cap of $4.51 billion, a PE ratio of 138.36 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same quarter in the prior year, the company earned ($0.02) earnings per share. The company’s revenue for the quarter was up 78.4% on a year-over-year basis. As a group, research analysts expect that ADMA Biologics, Inc. will post 0.49 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the sale, the director now owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is currently owned by company insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.